Windward Bio raised $165 million to push its long-acting anti-TSLP antibody into Phase 3, aiming to establish a twice-yearly dosing profile in asthma. The financing is framed as a “crossover” capital event to move late-stage and differentiate within a crowded respiratory field. The company’s strategy emphasizes convenience and persistence—two dimensions that can drive patient adherence and health-system adoption if efficacy and safety hold at scale. For the asthma pipeline ecosystem, the move puts additional pressure on competitors with more frequent dosing schedules and underscores that “interval length” is becoming a key competitive axis. Windward’s ability to maintain clinical performance while reducing dosing frequency will be the focal point as Phase 3 enrollment and interim updates progress.